AngioDynamics, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Yi Chen from H.C. Wainwright reiterated a Buy rating on the stock and has a $16.00 price target.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Yi Chen’s rating is based on AngioDynamics’ strong financial performance in FY25, where the company exceeded expectations in both revenue and net loss figures. The Med Tech segment showed significant growth, particularly with products like Auryon, AngioVac, and AlphaVac, which contributed to the overall positive outlook. The company also demonstrated a solid cash position, which is expected to support its operations in the near term.
Looking ahead to FY26, AngioDynamics has provided optimistic guidance, with expectations of continued growth in the Med Tech segment and a focus on execution. The company aims to achieve positive free cash flow and maintain a strong gross margin. These factors, combined with a favorable valuation based on comparative analysis with other medical technology firms, support Yi Chen’s Buy rating and the $16 price target for the stock.
In another report released yesterday, Canaccord Genuity also reiterated a Buy rating on the stock with a $17.00 price target.